Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.34 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL923312 | 0.93 | CACNA1H (0.36) | HDAC2HDAC1FFAR4PTGDR2RAD51 | |
| SCHEMBL925767 | 0.92 | RAD51 (0.35) | HDAC2HDAC1FFAR4RAD51CACNA1H | |
| SCHEMBL923122 | 0.91 | RAD51 (0.38) | HDAC2HDAC1FFAR4RAD51CACNA1H | |
| SCHEMBL924206 | 0.91 | AR (0.38) | FFAR4CACNA1H | |
| SCHEMBL923426 | 0.91 | RAD51 (0.35) | HDAC2HDAC1FFAR4RAD51CACNA1H | |
| SCHEMBL923676 | 0.90 | NR1H2 (0.34) | FFAR4RAD51CACNA1HNR1H2KMO | |
| SCHEMBL924172 | 0.89 | QPCT (0.36) | FFAR4PTGDR2RAD51CACNA1HTP53 | |
| SCHEMBL924688 | 0.87 | FFAR4 (0.35) | FFAR4PTGDR2RAD51CACNA1H | |
| SCHEMBL924053 | 0.86 | PTGER1 (0.36) | FFAR4RAD51TP53MDM2 | |
| SCHEMBL3887605 | 0.86 | THRA (0.43) | FFAR4RAD51CACNA1HKMOS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006225-B2 | Stable pharmaceutical composition | ASAHI KASEI PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| EP-2620431-A1 | Novel crystals of substituted phenylalkanoic acid and production process | Asahi Kasei Pharma Corporation (JP) | 2013-07-31 | — | — | EP | disclosed |
| EP-2045244-B1 | NOVEL CRYSTAL OF SUBSTITUTED PHENYLALKANOIC ACID AND PRODUCTION PROCESS | ASAHI KASEI PHARMA CORP (JP) | 2013-04-03 | — | — | EP | disclosed |
| US-7935720-B2 | Crystal of substituted phenylalkanoic acid ester and process for producing the same | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20110021593-A1 | NOVEL CRYSTAL OF SUBSTITUTED PHENYLALKANOIC ACID ESTER AND PROCESS FOR PRODUCING THE SAME | SHODA MOTOSHI | 2011-01-27 | — | — | US | disclosed |
| US-7838546-B2 | Crystal of substituted phenylalkanoic acid ester and process for producing the same | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-11-23 | — | — | US | disclosed |
| EP-2236135-A1 | STABLE PHARMACEUTICAL COMPOSITION | Asahi Kasei Pharma Corporation (JP) | 2010-10-06 | — | — | EP | disclosed |
| US-20100234440-A1 | NOVEL CRYSTAL OF SUBSTITUTED PHENYLALKANOIC ACID ESTER AND PROCESS FOR PRODUCING THE SAME | SHODA MOTOSHI | 2010-09-16 | — | — | US | disclosed |
| US-7754752-B2 | Crystals of substituted phenylalkanoic acid and method of producing the same | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-07-13 | — | — | US | disclosed |
| US-20100041725-A1 | STABLE PHARMACEUTICAL COMPOSITION | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20090312386-A1 | NOVEL CRYSTALS OF SUBSTITUTED PHENYLALKANOIC ACID AND METHOD OF PRODUCING THE SAME | ARIMOTO YUICHI | 2009-12-17 | — | — | US | disclosed |
| US-7560478-B2 | Crystal forms of substituted phenylalkanoic acids and process for producing the same | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-07-14 | — | — | US | disclosed |
| EP-2045244-A1 | NOVEL CRYSTAL OF SUBSTITUTED PHENYLALKANOIC ACID AND PRODUCTION PROCESS | Asahi Kasei Pharma Corporation (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-20080070967-A1 | Novel crystal forms of substituted phenylalkanoic acids and process for producing the same | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041725-A1 | STABLE PHARMACEUTICAL COMPOSITION | SLC5A1, SLC5A2, SLC2A9 | HDAC2 480/4885HDAC1 322/4885FFAR4 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.